AZD8154   Click here for help

GtoPdb Ligand ID: 11204

Synonyms: AZD-8154 | Example 1 [WO2018055040A1]
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: AZD8154 is one of the chemical structures in a patent from AstraZeneca that claims dual phosphatidylinositol 3-kinase (PI3K) δ/γ inhibitors [1]. Its discovery was formally disclosed by Perry et al., in June 2021 [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 149.19
Molecular weight 551.17
XLogP 3.45
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES C[C@H](N1Cc2c(C1=O)c(cc(c2)c1sc(nc1C)Nc1cccc(n1)N1CCCC1=O)S(=O)(=O)C)C1CC1
Isomeric SMILES C[C@H](N1Cc2c(C1=O)c(cc(c2)c1sc(nc1C)Nc1cccc(n1)N1CCCC1=O)S(=O)(=O)C)C1CC1
InChI InChI=1S/C27H29N5O4S2/c1-15-25(37-27(28-15)30-21-6-4-7-22(29-21)31-11-5-8-23(31)33)18-12-19-14-32(16(2)17-9-10-17)26(34)24(19)20(13-18)38(3,35)36/h4,6-7,12-13,16-17H,5,8-11,14H2,1-3H3,(H,28,29,30)/t16-/m0/s1
No information available.
Summary of Clinical Use Click here for help
AZD8154 was being evaluated in clinical trial as an inhalation therapeutic for asthma, but the Phase 2 NCT04187508 study was withdrawn due to "emerging pre-clinical toxicology findings".
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04187508 A Study to Evaluate the Effect of AZD8154 Administered Via Nebulizer Once Daily in Subjects With Mild Allergic Asthma Challenged With an Inhaled Allergen Phase 2 Interventional AstraZeneca Study withdrawn: due to detection of adverse pre-clinical toxicology.
NCT03436316 A Study to Evaluate the Safety, Tolerability and Absorption to the Blood After Administration of Single and Multiple Doses of AZD8154 in Healthy Participants. Phase 1 Interventional AstraZeneca 3